PillSense System for Detecting UGI Bleed
Primary Purpose
UGI Bleed, Upper Gastrointestinal Bleeding, Upper Gastrointestinal Bleed
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PillSense
Sponsored by
About this trial
This is an interventional diagnostic trial for UGI Bleed focused on measuring EnteraSense, PillSense, UGI Bleed, UGIB, Upper Gastrointestinal Bleeding, Upper Gastrointestinal Bleed, Upper Gastrointestinal
Eligibility Criteria
Inclusion Criteria
- Age >=18 years
- Ability to provide informed consent
- Clinical suspicion of UGIB
Exclusion Criteria:
- Circulatory or hemodynamic instability
- Known GI tract stricture
- Using an implantable electrical device
- Difficulties in swallowing pills the size of the capsule
- History of: achalasia or known esophageal dysmotility; gastroparesis; severe constipation; Crohn's disease; bowel obstruction
- Currently taking medications intended for stimulation of GI motility
- Currently pregnant or breastfeeding, or intend to become pregnant during the investigation
- Suspected or previously diagnosed obstructing gastrointestinal tumor
Sites / Locations
- Mayo Clinic
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PillSense (Active)
Arm Description
This is a single-arm, non-randomized study.
Outcomes
Primary Outcome Measures
Sensitivity
To assess the sensitivity of the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
Specificity
To evaluate the specificity of the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
Secondary Outcome Measures
PPV
To assess the positive predictive value (PPV) of the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
NPV
Negative predictive value (NPV) for the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
Transit
To evaluate the transit of the PillSense Capsule through the GI tract. Passage of the capsule will be monitored until capsule has passed from the body. If subject or study team is unable to determine capsule passage visually, a confirmation x-ray or other imaging will be used to determine if the capsule is still present in the body.
Full Information
NCT ID
NCT05385224
First Posted
March 22, 2022
Last Updated
June 29, 2023
Sponsor
EnteraSense Limited
Collaborators
Databean
1. Study Identification
Unique Protocol Identification Number
NCT05385224
Brief Title
PillSense System for Detecting UGI Bleed
Official Title
A Clinical Study to Evaluate Effectiveness and Safety of the PillSense System in Detecting Blood in the Stomach for the Evaluation of Upper Gastrointestinal Bleeding (UGIB)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
December 10, 2021 (Actual)
Primary Completion Date
September 7, 2022 (Actual)
Study Completion Date
September 13, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
EnteraSense Limited
Collaborators
Databean
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a prospective, non-randomized, open-label clinical investigation to evaluate feasibility, effectiveness and safety of the PillSense System, the transit of the PillSense Capsule through the GI tract, patient tolerability of the PillSense Capsule, and blood detection.
Detailed Description
Patient eligibility as set out in the inclusion/exclusion criteria for the clinical investigation will be reviewed prior to study enrollment. Prior to administering the PillSense Capsule, the PillSense Receiver will be paired with the PillSense Capsule. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule. The PillSense Receiver interprets the data and displays a result message "Blood detected" or "No Blood detected". The overall investigation from the PillSense Capsule activation and ingestion until the result message is displayed takes less than 10 minutes. Esophagogastroduodenoscopy (EGD) should be completed immediately or up to 4 hours after PillSense Capsule administration in each patient that receives a "Blood detected" or "No blood detected" result to confirm the result achieved with the PillSense System. The endoscopy will be conducted according to the site's standard of care. Prior to discharge each patient will undergo an X-Ray examination to evaluate for PillSense Capsule presence. Following discharge, if there is no verifiable evidence that the PillSense Capsule passed through the gastrointestinal tract (GIT) (such as a photograph of stool with capsule in it or photograph of the capsule alone), the patient may undergo an X-Ray examination at Day 7 ± 5 days and, if necessary, at Day 14± 7 days to ascertain the passage status of the PillSense Capsule. If the PillSense Capsule did not pass through the GIT, it should be removed by an endoscopic method.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
UGI Bleed, Upper Gastrointestinal Bleeding, Upper Gastrointestinal Bleed
Keywords
EnteraSense, PillSense, UGI Bleed, UGIB, Upper Gastrointestinal Bleeding, Upper Gastrointestinal Bleed, Upper Gastrointestinal
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
131 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PillSense (Active)
Arm Type
Experimental
Arm Description
This is a single-arm, non-randomized study.
Intervention Type
Diagnostic Test
Intervention Name(s)
PillSense
Intervention Description
The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
Primary Outcome Measure Information:
Title
Sensitivity
Description
To assess the sensitivity of the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
Time Frame
Day 1
Title
Specificity
Description
To evaluate the specificity of the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
PPV
Description
To assess the positive predictive value (PPV) of the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
Time Frame
Day 1
Title
NPV
Description
Negative predictive value (NPV) for the PillSense System in detecting the presence of blood in the stomach. The investigational device returns a result of either "Blood detected" or "No blood detected".
Time Frame
Day 1
Title
Transit
Description
To evaluate the transit of the PillSense Capsule through the GI tract. Passage of the capsule will be monitored until capsule has passed from the body. If subject or study team is unable to determine capsule passage visually, a confirmation x-ray or other imaging will be used to determine if the capsule is still present in the body.
Time Frame
Day 1 through Day 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Age >=18 years
Ability to provide informed consent
Clinical suspicion of UGIB
Exclusion Criteria:
Circulatory or hemodynamic instability
Known GI tract stricture
Using an implantable electrical device
Difficulties in swallowing pills the size of the capsule
History of: achalasia or known esophageal dysmotility; gastroparesis; severe constipation; Crohn's disease; bowel obstruction
Currently taking medications intended for stimulation of GI motility
Currently pregnant or breastfeeding, or intend to become pregnant during the investigation
Suspected or previously diagnosed obstructing gastrointestinal tumor
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Collins
Organizational Affiliation
Technical Operations Director
Official's Role
Study Director
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
PillSense System for Detecting UGI Bleed
We'll reach out to this number within 24 hrs